LatticeworkTHE EVIDENCE DESK
← Discover companies

Investigate / reported ownership

ABBV

Abbvie Inc

8 tracked reported owners · snapshot updated 2026-10-04. Delayed disclosures, not live holdings or an investment recommendation.

Explore company research →Revisit Saved →

Who reports owning ABBV?

Select a manager to inspect their portfolio. Reports may cover different quarters; portfolio weights describe disclosed long 13F holdings, not total economic exposure.

Sort↑
Showing 5 of 8

Go beyond ownership.

AbbVie develops and markets medicines across immunology, neuroscience, oncology and aesthetics. Products are sold through wholesalers, distributors and other healthcare channels, with some products sold directly to physicians and licensed providers.

Question to investigate: Can AbbVie replace revenue lost to patent competition while broadening beyond Skyrizi and Rinvoq and managing government price-setting?

Company research reviewed 2026-10-02; a dated source-linked starting point, not the investors’ stated reasons.

Understand the business and investment case →
Filing dates and original SEC sources

Keep your next step small.

Save the company and inspect its evidence. Recording a private view is optional and requires a separate, explicit save.

Record my own view →
Optional email follow

Latticework Follow

Follow ABBV

Email me only when a reviewed weekly edition contains a material new decision about ABBV: a new position, exit, or a large share-count change that also clears the size threshold. There may be quiet weeks.

Confirm by email. Manage or stop follows in one click. See our privacy notice.

Long US 13F disclosures omit shorts and can be amended. CUSIP 00287Y109. No current price, valuation or manager motive is inferred.